Publication Date
2-15-2024
Journal
American Journal of Respiratory and Critical Care Medicine
DOI
10.1164/rccm.202307-1154WS
PMID
38113442
PMCID
PMC10878386
PubMedCentral® Posted Date
12-19-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
United States, Humans, National Heart, Lung, and Blood Institute (U.S.), Lakes, Idiopathic Pulmonary Fibrosis, Risk Factors, Biomedical Research, interstitial lung disease, pulmonary fibrosis
Abstract
Despite progress in elucidation of disease mechanisms, identification of risk factors, biomarker discovery, and the approval of two medications to slow lung function decline in idiopathic pulmonary fibrosis and one medication to slow lung function decline in progressive pulmonary fibrosis, pulmonary fibrosis remains a disease with a high morbidity and mortality. In recognition of the need to catalyze ongoing advances and collaboration in the field of pulmonary fibrosis, the NHLBI, the Three Lakes Foundation, and the Pulmonary Fibrosis Foundation hosted the Pulmonary Fibrosis Stakeholder Summit on November 8–9, 2022. This workshop was held virtually and was organized into three topic areas: 1) novel models and research tools to better study pulmonary fibrosis and uncover new therapies, 2) early disease risk factors and methods to improve diagnosis, and 3) innovative approaches toward clinical trial design for pulmonary fibrosis. In this workshop report, we summarize the content of the presentations and discussions, enumerating research opportunities for advancing our understanding of the pathogenesis, treatment, and outcomes of pulmonary fibrosis.
Included in
Internal Medicine Commons, Medical Sciences Commons, Pediatrics Commons, Pulmonology Commons, Respiratory Tract Diseases Commons